TW202304993A - 靶向腫瘤及/或免疫細胞之結合劑 - Google Patents

靶向腫瘤及/或免疫細胞之結合劑 Download PDF

Info

Publication number
TW202304993A
TW202304993A TW111112543A TW111112543A TW202304993A TW 202304993 A TW202304993 A TW 202304993A TW 111112543 A TW111112543 A TW 111112543A TW 111112543 A TW111112543 A TW 111112543A TW 202304993 A TW202304993 A TW 202304993A
Authority
TW
Taiwan
Prior art keywords
amino acid
acid sequence
seq
binding agent
domain
Prior art date
Application number
TW111112543A
Other languages
English (en)
Chinese (zh)
Inventor
姚書剛
理查 瓦根查克
崔雲
文陽 侯
傑克西 圖盧茲
伊雷傑斯 溫濟斯
安娜 卡札涅茲
宮立瑩
米立卡 克里斯蒂齊
曉葳 王
希巴 札哈達
克魯斯 路易斯 達
士範 楊
Original Assignee
加拿大商木曾路生物科技公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 加拿大商木曾路生物科技公司 filed Critical 加拿大商木曾路生物科技公司
Publication of TW202304993A publication Critical patent/TW202304993A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW111112543A 2021-03-31 2022-03-31 靶向腫瘤及/或免疫細胞之結合劑 TW202304993A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202163168606P 2021-03-31 2021-03-31
US63/168,606 2021-03-31
US202163249784P 2021-09-29 2021-09-29
US63/249,784 2021-09-29
US202263301305P 2022-01-20 2022-01-20
US63/301,305 2022-01-20
WOPCT/CA2022/050442 2022-03-25
PCT/CA2022/050442 WO2022204793A1 (en) 2021-03-31 2022-03-25 Binding agents targeting tumors and/or immune cells

Publications (1)

Publication Number Publication Date
TW202304993A true TW202304993A (zh) 2023-02-01

Family

ID=83455216

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111112543A TW202304993A (zh) 2021-03-31 2022-03-31 靶向腫瘤及/或免疫細胞之結合劑

Country Status (7)

Country Link
US (1) US20240166739A1 (cg-RX-API-DMAC7.html)
EP (1) EP4314076A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024512741A (cg-RX-API-DMAC7.html)
AR (1) AR125264A1 (cg-RX-API-DMAC7.html)
CA (1) CA3174330A1 (cg-RX-API-DMAC7.html)
TW (1) TW202304993A (cg-RX-API-DMAC7.html)
WO (1) WO2022204793A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4599066A1 (en) * 2022-10-03 2025-08-13 Kisoji Biotechnology Inc. Multispecific binding agents targeting dopamine receptor d2 and methods of use thereof
CN120265659A (zh) * 2022-10-25 2025-07-04 加拿大商木曾路生物科技公司 靶向表达cd36的肿瘤细胞的结合剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009508521A (ja) * 2005-09-23 2009-03-05 アカデミッシュ ジーケンハイス レイデン タンパク凝集に関連する疾患の診断予防及び治療のためのvhh
CA2747644C (en) * 2008-12-19 2023-01-24 Ablynx N.V. Method for generation of immunoglobulin sequences
WO2011051327A2 (en) * 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
US20180222966A1 (en) * 2013-04-29 2018-08-09 Agrosavfe N.V. Transgenic plant comprising a polynucleotide encoding a variable domain of heavy-chain antibody
US10874685B2 (en) * 2014-04-17 2020-12-29 The Royal Institution For The Advancement Of Learning/Mcgill University Pancreatic cancer therapy and diagnosis
CA2975655C (en) * 2015-02-05 2023-09-19 Janssen Vaccines & Prevention B.V. Binding molecules directed against influenza hemagglutinin and uses thereof
CA3065999A1 (en) * 2017-05-24 2018-11-29 Nanosomix, Inc. Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders
WO2019179434A1 (en) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/cd47 antibody molecules
CN114072426B (zh) * 2019-07-08 2024-01-26 南京金斯瑞生物科技有限公司 抗cd47/抗pd-1双特异抗体及其制备方法和应用

Also Published As

Publication number Publication date
US20240166739A1 (en) 2024-05-23
CA3174330A1 (en) 2022-09-30
EP4314076A1 (en) 2024-02-07
JP2024512741A (ja) 2024-03-19
AR125264A1 (es) 2023-06-28
WO2022204793A1 (en) 2022-10-06
EP4314076A4 (en) 2025-07-09

Similar Documents

Publication Publication Date Title
TWI830761B (zh) 針對cldn18.2和cd3之抗體構建體
TWI907375B (zh) 多肽、蛋白質複合物及其製造方法
US10253104B2 (en) Bispecific antibodies against CD3ϵ and BCMA
JP2021129564A (ja) 共通軽鎖および使用方法
US20170327579A1 (en) Bispecific antibodies against cd3epsilon and bcma
CN111133003A (zh) 新型双特异性多肽复合物
US20230062624A1 (en) Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
US20240166739A1 (en) Binding agents targeting tumors and/or immune cells
CN117157322A (zh) 靶向肿瘤和/或免疫细胞的结合剂
US20250313638A1 (en) Multispecific binding agents targeting dopamine receptor d2 and methods of use thereof
US20250326857A1 (en) Binding agents targeting cd36-expressing tumor cells
KR20250158060A (ko) 항-cldn6 및 항-cd3 다중특이적 항체 및 사용 방법
KR20250156803A (ko) 항-cd3 다중특이적 항체 및 사용 방법
HK40122804A (en) Antibody molecules that bind pd-l1 and cd137
HK1218299B (en) Bispecific antibodies against cd3epsilon and bcma